Existing liquid biopsy tests are unable to confidently differentiate between cancer patients who are cured and those who will experience progression when disease burden is low. Spontaneous and benign SNVs occur at high enough frequency to obscure the scant presence of tumor-associated SNVs. The inherent error rate of NGS-based testing further masks low-allelic frequency mutations. This background noise results in missed relapses hiding in plain sight.
Single nucleotide variations are common and counting them can be inconclusive due to the inherent error rates of NGS. But Foresight CLARITY is powered by phased variants (PVs), which are multiple SNVs found on a single sequencing read, can be uniquely attributed to malignant cells. PVs commonly occur in all types of cancers, and by specifically monitoring tumor-specific PVs, we have attained unmatched MRD sensitivity.
By leveraging this untapped biology in cancers, we’re able to identify MRD at levels below the detection limit of conventional NGS-based ctDNA assays. We cut the noise that leading error suppression methods like duplex sequencing and barcoding can’t.
Foresight CLARITY detects MRD across liquid and solid tumors with unprecedented sensitivity and specificity.
In lymphomas and other blood cancers, validated mutational signatures eliminate the need for customized assays, expediting MRD-guided research and treatment with personalized analysis, from off-the-shelf panels.
Lymphoma & Blood Cancers
Unlike personalized MRD assays that require exome sequencing and patient-specific panel design, Foresight CLARITY for Lymphoma is an off-the-shelf panel that can be used to measure extremely low amounts of ctDNA from plasma, giving up to 100X improved sensitivity of cancer detection that results in identifying recurrence an average of 200 days earlier1 than conventional methods.
Assay pre-treatment plasma DNA for personalized PV genotyping via targeted sequencing.
No tumor sample needed.
Mid- and end-of-treatment plasma ctDNA used for MRD
assessment.
Treatment plan is informed by ctDNA levels.
Post-treatment plasma DNA used for longitudinal cancer surveillance.
No tumor samples or customization needed
Assays performed at our CLIA-certified lab
Solid Tumors
∟
Foresight CLARITY for Solid Tumors is personalized based on patient-specific phased variants that are identified with whole-genome sequencing. It offers the same degree of sensitivity as Foresight CLARITY for Lymphoma and has the ability to track oncogenic and clinically relevant SNVs in addition to other tumor-specific phased variants.
More About Foresight CLARITY for Solid TumorsUse our Foresight CLARITY MRD platform to enrich patient populations for those with the highest likelihood of responding to a given therapy. Screen less patients and complete trial recruitment faster.
Foresight CLARITY is also available outside of our CLIA lab as a ctDNA research assay, and can answer a wide variety of pressing questions in translational research. Quantify and monitor disease burden over time in both solid tumors and blood cancers.
